HomeReleasesSkye Salud AI medical platform advances to primary...
Releases

Skye Salud AI medical platform advances to primary care trials in Mexico

Skye Salud AI medical platform advances to primary care trials in Mexico

Following a successful Phase 1 rheumatology assessment, the Skye Salud medical evidence platform has entered Phase 2 clinical evaluation. The collaboration between Brand Engagement Network, Grupo Skye, and KNOBLOCH Information Group aims to test how AI-driven information retrieval performs within the diverse demands of primary care settings.

The expansion marks a significant shift from the controlled, specialty-specific environment of the initial pilot to a broader range of clinical topics. During the first phase, developers focused on validating the platform’s ability to provide accurate, cited responses grounded in trusted medical literature and clinical guidelines. Dr. Ruy Carrasco, Chief Medical Information Officer, noted that this foundation ensures the current expansion into primary care maintains the same rigorous evidence thresholds and source transparency protocols.

By incorporating Spanish-language clinical content optimized for the Mexican market, the partners are exploring how conversational AI can improve physician access to reliable medical data. Tyler Luck, CEO of Brand Engagement Network, described the transition as a vital step in assessing the platform’s performance across a more heterogeneous spectrum of clinical presentations. The results of this second phase will determine the roadmap for future development, regulatory considerations, and potential commercial deployment across the Latin American healthcare sector.

Share:TelegramXFacebook

Read Also

Comments (0)

Leave a comment

No comments yet. Be the first!